Canada’s missing life sciences industrial strategy is leaving economic growth on the table

The federal Biomanufacturing and Life Sciences Strategy, released in 2021, did not result in needed policy changes or alignment of federal departments and investments. In contrast, other top-tier countries place life sciences at the centre of industrial strategies and align the sector with talent, trade, research and development, innovation and infrastructure.

People walking past the West Block on Parliament Hill. Canada need a life sciences industrial policy that leverages our strengths, writes Michelle McLean, president and CEO of HealthCareCAN.The Hill Times photograph by Andrew Meade

Opinion

BY MICHELLE MCLEAN

February 2, 2026

Life sciences innovation is not just about saving lives; it is an economic growth engine. Breakthroughs in biotechnology, pharmaceuticals, medical devices, and digital health strengthen a healthy and productive workforce, attract top talent, and spur economic growth and deve...

To keep reading, subscribe and become a political insider.

Only $7.76 a week for an annual subscription.

Enjoy unlimited website access and the digital newspaper.

Cancel anytime.

Already a Subscriber?

Get Tuesdays: Innovation & Industry Newsletter

The policies, decisions, and people working on investment and regulation in the industry and innovation realm.

By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy